65,437 trials
Chronic Pain · Migraine · Chronic Pain Syndrome
Primary: Brief Pain Inventory-short Form (BPI-SF) — 5.33; 5.35; 4.51; 5.16 score on a scale
Opioid Use · Loneliness
Primary: Mean Change in Loneliness — -8.3; -10.3 score on a scale — p=>.05
Melanoma · Merkel Cell Carcinoma · Other Solid Tumors
Primary: Best Response — 1; 1; 0; 0 Participants
Pneumonia
Primary: Extended-Spectrum Days Of Antibacterial Therapy (ES-DOT) Per Empiric Day — 38690; 27971 Extended-Spectrum Days-of-Therapy
Cancer · Solid Tumor
Primary: Module 1 - Safety and Tolerability of RXC004 by Assessment of Whether Any Dose Limiting Toxicities (DLT) Arise From First Dose Until the End of 21 Days of Continuous…
Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma Activated B-Cell Type · Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type
Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659
HIV Infections
Primary: Safety Endpoint: Proportion of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities Among Participants Who Receive…
Carcinoma · Carcinoma, Hepatocellular · Liver Neoplasm
Primary: Mean Absorbed Dose (Gy) for the Whole Body — 0.941 mGy
Cardiovascular Diseases · Acute Coronary Syndrome · Depression
Primary: Recruitment Feasibility: Percent of Participants Screened Eligible — 48 Participants
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Primary: Comparison of Total Plaque Volume — 0.91 Pearson's correlation statistic
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events
Helicobacter Pylori Infection
Primary: Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs) — 6; 9; 4; 3 participants
Musculoskeletal Pain · Chronic Shoulder Pain · Shoulder Tendinopathy
Primary: Change in the Shortened Disabilities of the Arm, Shoulder and Hand Questionnaire (QuickDASH) — 15.5; 13.1 units on a scale — p=0.75
Hematopoietic and Lymphoid Cell Neoplasm
Primary: Cancer and Treatment Distress (CTXD) — 23.4; 22.6 percentage of participants — p=0.90
Eye Diseases · Postcataract Aphakia · Cataract
Primary: Mean Photopic Monocular logMAR Best Corrected Distance Visual Acuity (BCDVA) at 4 Meters in First Operative Eyes — 0.018; -0.028 logMAR — p=<0.0001